secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000318154-23-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q2 2023: Revenue up 6% to $7.0B; Non-GAAP EPS rises 8% to $5.00
---------------------------------------------------------------------

- Total revenues increased 6% to $7.0B; product sales volume growth of 11% partially offset by FX and price.
- GAAP EPS $2.57 (up 5% YoY); Non-GAAP EPS $5.00 (up 8% YoY), driven by record revenues.
- Free cash flow $3.8B vs $1.7B in Q2 2022, due to timing of tax payments and higher income.
- Pipeline: positive top-line for tarlatamab in small cell lung cancer and LUMAKRAS+Vectibix in colorectal cancer.
- Volume growth double-digit for EVENITY, BLINCYTO, Repatha, LUMAKRAS, Vectibix, KYPROLIS, Nplate, AMJEVITA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/0000318154-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815423000049/amgn-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000318154-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer